CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
D	PIK3CA	K111N	Predictive	Does Not Support	Resistance	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Baselga et al., 2016
D	PIK3CA	I391M	Predictive	Does Not Support	Resistance	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Baselga et al., 2016
C	KIT	D820Y	Predictive	Supports	Resistance	Melanoma	Imatinib	Carvajal et al., 2011
B	MGMT	Underexpression	Predictive	Supports	Sensitivity/Response	Glioblastoma	Temozolomide	Chinot et al., 2007
B	MGMT	Underexpression	Predictive	Supports	Sensitivity/Response	High Grade Glioma	Temozolomide	Kreth et al., 2011
B	MGMT	Underexpression	Predictive	Supports	Sensitivity/Response	Glioblastoma	Temozolomide	Watanabe et al., 2011
D	FGFR1	Expression	Predictive	Supports	Sensitivity/Response	Sarcoma	Fexagratinib,Infigratinib,FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074	Chudasama et al., 2017
C	KIT	N822K	Predictive	Supports	Resistance	Gastrointestinal Stromal Tumor	Imatinib	Heinrich et al., 2006
C	KIT	Y823D	Predictive	Supports	Resistance	Gastrointestinal Stromal Tumor	Imatinib	Heinrich et al., 2006
C	KIT	C809G	Predictive	Supports	Resistance	Gastrointestinal Stromal Tumor	Imatinib	Heinrich et al., 2006
C	KIT	D820A	Predictive	Supports	Resistance	Gastrointestinal Stromal Tumor	Imatinib	Heinrich et al., 2006
C	KIT	D820G	Predictive	Supports	Resistance	Gastrointestinal Stromal Tumor	Imatinib	Heinrich et al., 2006
C	KIT	D816H	Predictive	Supports	Resistance	Gastrointestinal Stromal Tumor	Imatinib	Heinrich et al., 2006
C	KIT	T670I	Predictive	Supports	Resistance	Gastrointestinal Stromal Tumor	Imatinib	Heinrich et al., 2006
B	ATM	Mutation	Prognostic	Supports	Poor Outcome	Chronic Lymphocytic Leukemia		Guarini et al., 2012
C	BRAF	Amplification	Predictive	Supports	Resistance	Colorectal Cancer	Dabrafenib,Panitumumab	Ahronian et al., 2015
B	NRAS	Mutation	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Binimetinib,Ribociclib	Vu et al., 2016
D	IDH1	Mutation	Predictive	Supports	Sensitivity/Response	Brain Glioma	Olaparib	Sulkowski et al., 2017
B	MAP2K1	K57N	Prognostic	Supports	Poor Outcome	Lung Adenocarcinoma		Arcila et al., 2015
B	CTAG1B	Overexpression	Predictive	Supports	Sensitivity/Response	Multiple Myeloma	Letetresgene Autoleucel	Rapoport et al., 2015
B	CTAG2	Overexpression	Predictive	Supports	Sensitivity/Response	Multiple Myeloma	Letetresgene Autoleucel	Rapoport et al., 2015
D	KRAS	A146T	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	Janakiraman et al., 2010
A	v::NTRK1	Fusion	Predictive	Supports	Sensitivity/Response	Solid Tumor	Entrectinib	Drilon et al., 2017
B	v::NTRK3	Fusion	Predictive	Supports	Sensitivity/Response	Cancer	Entrectinib	Drilon et al., 2017
C	SQSTM1::NTRK1	Fusion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Entrectinib	Drilon et al., 2017
A	v::ROS1	Fusion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Entrectinib	Drilon et al., 2017
B	v::ALK	Fusion	Predictive	Supports	Sensitivity/Response	Cancer	Entrectinib	Drilon et al., 2017
C	LMNA::NTRK1	Fusion	Predictive	Supports	Sensitivity/Response	Colorectal Adenocarcinoma	Entrectinib	Russo et al., 2016
B	TP53	Wildtype	Predictive	Supports	Sensitivity/Response	Leukemia	RG7112	Andreeff et al., 2016
B	TP53	Deleterious Mutation	Predictive	Supports	Resistance	Leukemia	RG7112	Andreeff et al., 2016
B	DCC	EXPRESSION	Prognostic	Supports	Better Outcome	Colorectal Cancer		Shibata et al., 1996
B	CTNNB1	S45P	Diagnostic	Supports	Positive	Desmoid Tumor		Lazar et al., 2008
B	CTNNB1	S45F	Prognostic	Supports	Poor Outcome	Desmoid Tumor		Lazar et al., 2008
D	ARID1A	Loss	Predictive	Supports	Sensitivity/Response	Ovarian Clear Cell Carcinoma	Dasatinib	Miller et al., 2016
D	PIK3CA	E545K	Predictive	Supports	Sensitivity/Response	Cervix Carcinoma	Cisplatin,Pictilisib	Arjumand et al., 2016
D	PIK3CA	E545K	Predictive	Supports	Resistance	Cervical Cancer	Cisplatin	Arjumand et al., 2016
C	ALK	F1245V	Predictive	Supports	Sensitivity/Response	Neuroblastoma	Entrectinib	Drilon et al., 2017
D	MERTK	OVEREXPRESSION	Predictive	Supports	Sensitivity/Response	Melanoma	UNC1062	Schlegel et al., 2013
B	TP53	CONSERVED DOMAIN MUT	Prognostic	Supports	Poor Outcome	Ovarian Cancer		Reles et al., 2001
D	FLT3	D835V	Predictive	Supports	Resistance	Acute Myeloid Leukemia	Tandutinib	Clark et al., 2004
D	FLT3	D835V	Predictive	Does Not Support	Sensitivity/Response	Acute Myeloid Leukemia	Sunitinib	Yee et al., 2004
B	TP53	Overexpression	Predictive	Supports	Resistance	Ovarian Cancer	Carboplatin,Cisplatin	Reles et al., 2001
D	EGFR	Amplification	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Rociletinib,Osimertinib	Nukaga et al., 2017
B	EGFR	Mutation	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Douillard et al., 2010
C	KIT	V559D	Predictive	Supports	Sensitivity/Response	Gastrointestinal Stromal Tumor	Imatinib	Cameron et al., 2011
D	FLT3	D835V	Predictive	Supports	Sensitivity/Response	Acute Myeloid Leukemia	AS602868,Tyrphostin AG 1296	Griessinger et al., 2007
D	MET	Overexpression	Predictive	Supports	Resistance	Uveal Melanoma	Trametinib,Selumetinib	Cheng et al., 2015
B	CTNNB1	T41A	Prognostic	Supports	Better Outcome	Desmoid Tumor		Lazar et al., 2008
C	GNAS	R201H	Predictive	Supports	Sensitivity/Response	Follicular Thyroid Carcinoma	Radioactive Iodine	Lu et al., 2016
B	GNA11	Mutation	Predictive	Supports	Sensitivity/Response	Uveal Melanoma	Cabozantinib	Daud et al., 2017

Page 42 of 96

Previous Next